Abbott Laboratories (NYSE:ABT) Updates Q2 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.250-1.310 for the period, compared to the consensus earnings per share estimate of 1.340. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.380-5.580 EPS.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $101.55 on Thursday. The company’s 50-day moving average is $108.45 and its two-hundred day moving average is $119.18. The firm has a market capitalization of $176.86 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 1.61 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1-year low of $99.05 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, meeting the consensus estimate of $1.15. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Analyst Ratings Changes

A number of research firms have commented on ABT. The Goldman Sachs Group decreased their price target on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Evercore cut their price objective on Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Leerink Partners cut their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $134.58.

Insider Transactions at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Abbott Laboratories by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 23,434,760 shares of the healthcare product maker’s stock worth $2,936,141,000 after acquiring an additional 188,616 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Abbott Laboratories by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,189,528 shares of the healthcare product maker’s stock valued at $1,652,517,000 after buying an additional 52,191 shares in the last quarter. Amundi boosted its holdings in shares of Abbott Laboratories by 28.3% in the 4th quarter. Amundi now owns 8,185,642 shares of the healthcare product maker’s stock valued at $1,025,578,000 after buying an additional 1,803,975 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Abbott Laboratories by 2.0% in the 3rd quarter. Raymond James Financial Inc. now owns 5,536,178 shares of the healthcare product maker’s stock valued at $741,515,000 after buying an additional 107,843 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Abbott Laboratories by 29.7% in the 4th quarter. California Public Employees Retirement System now owns 5,206,580 shares of the healthcare product maker’s stock valued at $652,332,000 after buying an additional 1,193,410 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.